within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AF05_Amifostine;

model Amifostine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.38888888888889e-05,
    adminDuration = 600,
    adminMass = 910 / 1000000,
    adminCount = 1,
    Vd = 0.024,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.086,
    k12 = 3.3333333333333335e-05,
    k21 = 3.3333333333333335e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Amifostine</td></tr><tr><td>ATC code:</td><td>V03AF05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>910</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>24</td><td>L</td></tr>
    <tr><td>clearance:</td><td>230</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Amifostine is a cytoprotective adjuvant used to reduce the toxic side effects of chemotherapy and radiation therapy. It acts as a prodrug that is dephosphorylated by alkaline phosphatase to an active metabolite, which then protects normal (but not cancer) cells from DNA-damaging agents. It is approved for use to decrease xerostomia in radiation treatment for head and neck cancer, and to reduce cumulative renal toxicity with cisplatin use in advanced ovarian cancer.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult cancer patients receiving a standard intravenous infusion of amifostine prior to chemotherapy.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AF05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Amifostine;
